Hematemesis: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 15: Line 15:
   MeshNumber    = C23.550.414.788.400 |
   MeshNumber    = C23.550.414.788.400 |
}}
}}
{{SI}}
{{Hematemesis}}
{{CMG}} {{JFS}}
{{CMG}} {{JFS}}
==Overview==
==Overview==

Revision as of 02:58, 5 September 2012

For patient information click here

Hematemesis
ICD-10 K92.0
ICD-9 578.0
DiseasesDB 30745
MeSH C23.550.414.788.400

Hematemesis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hematemesis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hematemesis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hematemesis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hematemesis

CDC on Hematemesis

Hematemesis in the news

Blogs on Hematemesis

Directions to Hospitals Treating Hematemesis

Risk calculators and risk factors for Hematemesis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor-In-Chief: John Fani Srour, M.D.

Overview

Hematemesis or haematemesis is the vomiting of blood. The source is generally the upper gastrointestinal tract (UGI). Patients can easily confuse it with hemoptysis (coughing up blood), although the former is more common. The most common causes of upper GI bleeding include bleeding peptic ulcer disease, gastritis, and variceal bleed. A nasogastric tube lavage that yields blood or coffee-ground like material confirms the diagnosis and predicts whether bleeding is caused by a high-risk lesion. The initial evaluation of the patient with UGI bleeding involves an assessment of hemodynamic stability and resuscitation if necessary. Upper endoscopy usually follows, with the goal of both diagnosis, and in some circumstances, treatment of the specific disorder. Important elements of the history include use of NSAIDs, alcohol, history of liver disease or variceal bleeding, history of ulcers, weight loss, dysphagia, or an abdominal aortic aneurysm (AAA). The latter may indicate aortoenteric fistula. Any recent surgical procedure especially one involving the GI tract is also relevant. Endoscopic, clinical, and laboratory features are useful for risk stratification of patients who present with UGI bleeding. In addition, gastroenterology and surgical consultation are usually required, especially for high risk patients.

Significant Associated Signs and Symptoms

Associated symptoms and signs of hematemesis may include:

  • Signs of liver disease (ascites, hepatomegaly, telangiectasia, etc)
  • Any esopho-gastric symptoms, such as nausea, vomiting, and epigastic tenderness may indicate peptic ulcer disease.
  • Dark colored, tar like stools (a condition known as melena). This usually supports upper GI bleed as opposed to lower GI bleed.
  • Symptoms of weight loss, early satiety, or loss of appetite raise suspicions for malignant process such as gastric adenocarcinoma.
  • Any significant psychiatric history or symptoms of severe depression or psychosis may indicate iatrogenic upper GI bleed related to pill esophagitis, foreign body ingestion, or munchausen syndrome by proxy (a reason for recurrent haemtemesis in children).
  • Vesicular rash of the lips or the oral cavity may indicate esophagitis related to herpes simplex virus infection.
  • Oral thrush in combination with dysphagia and/or odynophagia usually indicate candida esophagitis.
  • Associated bleeding in other organs ( skin, mucosal bleed, GU, joints, etc) indicates coagulopathy ( ITP, hemophila, heparin, von willebrand disease, etc).
  • Signs of associated congential or inherited disease such as mucosal telangiectasias in hereditary hemorrhagic telangiectasia, intestinal duplication, congenital cysts, etc..
  • Facial flushing, intermittent diarrhea, and abdominal pain indicate carcinoid syndrome, a rare cause of upper GI bleed.
  • Severe and diffuse upper GI ulcerations with chronic diarrhea usually indicate Zollinger Ellison syndrome or gastrenoma.

Complete Differential Diagnosis of the Causes of Hematemesis

(In alphabetical order)

Complete Differential Diagnosis of the Causes of Hematemesis

(By organ system)

Cardiovascular Arterial, venous, or other vascular malformations, Idiopathic angiomas, Dieulafoy's lesion, Angiodysplasia, Aortic Coarctation, Aortoenteric fistula
Chemical / poisoning Caustic ingestion
Dermatologic No underlying causes
Drug Side Effect Abciximab, Aspirin, Clopidogrel , Tetracycline (pill induced esophagitis), Ticlopidine, Quinidine, Drotrecogin alfa, Heparin, Coumadin, Alendronate, Tetracycline, Quinidine, Potassium chloride, Nonsteroidal antiinflammatory drugs,
Ear Nose Throat No underlying causes
Endocrine No underlying causes
Environmental No underlying causes
Gastroenterologic Portal hypertension, Esophageal varices, Gastric varices, Duodenal varices, Portal hypertensive gastropathy, Acute esophageal necrosis (AEN), Pseudomembranous esophagitis, Watermelon stomach (gastric antral vascular ectasia), Mallory-Weiss tear, Aortoenteric fistula, Carcinoid, Cow's milk allergy, Dieulafoy's lesion, Esophageal cancer, Esophageal dilatation, Esophageal melanosis, Esophagitis, Helicobacter pylori, Hemobilia, Hemosuccus pancreaticus, Hereditary hemorrhagic telangiectasia, Heterotopic pancreatic tissue, Intestinal duplication, Parasites, Schistosomiasis
Genetic Duplication cysts, Ehlers-Danlos syndrome, Hereditary hemorrhagic telangiectasia, Osler-Weber-Rendu syndrome, Intestinal duplication
Hematologic Ticlopidine, Clopidogrel, Hemophilia, Drug-induced thrombocytopenia, Von Willebrand disease, Idiopathic thrombocytopenic purpura, Coagulopathy, Disseminated intravascular coagulation, Drotrecogin alfa, Osler-Weber-Rendu syndrome
Iatrogenic Radiation-induced telangiectasia, Traumatic or post-surgical, Mallory-Weiss tear, Foreign body ingestion, pill induced esophagitis, Post-surgical anastamosis

Aortoenteric fistula, Post gastric/duodenal polypectomy, Munchausen syndrome by proxy, Caustic ingestion, Esophageal dilatation, Foreign body ingestion

Infectious Disease Helicobacter pylori, Cytomegalovirus, Herpes simplex virus, Candida albicans, Parasites, Crimean-Congo hemorrhagic fever, Schistosomiasis
Musculoskeletal / Ortho No underlying causes
Neurologic No underlying causes
Nutritional / Metabolic No underlying causes
Obstetric/Gynecologic No underlying causes
Oncologic Leiomyoma, Lipoma, Polyp (hyperplastic, adenomatous, hamartomatous),

Adenocarcinoma, Lymphoma, Kaposi's sarcoma, Carcinoid, Melanoma, Metastatic tumor, Kasabach-Merritt syndromes, Systemic mastocytosis, Zollinger Ellison syndrome,

Opthalmologic No underlying causes
Overdose / Toxicity No underlying causes
Psychiatric Munchausen syndrome by proxy, Stress-induced ulcer,
Pulmonary No underlying causes
Renal / Electrolyte No underlying causes
Rheum / Immune / Allergy Cow's milk allergy, Vasculitis
Sexual No underlying causes
Trauma No underlying causes
Urologic No underlying causes
Miscellaneous Heterotopic pancreatic tissue


General Management

The most common causes of upper GI bleeding include bleeding peptic ulcer disease, gastritis, and variceal bleed related to hepatic cirrhosis. This management section discusses general treatment of bleeding related to these common causes: In general, individuals who are at low risk for recurrent or life-threatening hemorrhage may be suitable for early hospital discharge or even outpatient care. All patients with hemodynamic instability or active bleeding should be admitted to an intensive care unit for resuscitation and close observation. Two large caliber peripheral catheters or a central venous line should be inserted for intravenous access. Gastroenterological consultation should be obtained. A surgical consultation can be obtained in high-risk patients. These patients should also receive packed red blood cell transfusions to maintain the hematocrit above 30 percent. In general, patients with upper GI bleeding (high and low risk patients) should be treated with an intravenous Protein pump inhibitor (PPI) at presentation until confirmation of the cause of bleeding, after which the need for specific therapy can be determined. Protein pump inhibitors are used because the most common causes of GI bleed are gastritis and peptic ulcer disease. Patients known to have cirrhosis who present with upper GI bleeding should receive antibiotics, preferably before endoscopy, as bacterial infections are present in up to 20 percent of these patients. Somatostatin may also reduce the risk of bleeding due to variceal and nonvariceal causes.

Prophylaxis Against Bleed From Variceal Hemorrhage and Ulceration

  • Primary prophylaxis against variceal hemorrhage is indicated because of high rate of bleeding from esophageal varices and the high mortality associated with bleeding. Prophylactic propranolol or nadolol therapy is the only cost-effective therapy in this setting.
  • Prophylaxis against stress ulceration maybe also indicated for ICU patients with any of the following characteristics:
  1. Coagulopathy
  2. Mechanical ventilation for more than 2 days
  3. History of GI ulceration or bleeding with the past year
  4. Two or more of the following risk factors — sepsis, ICU admission lasting >1 week, occult GI bleeding lasting ≥6 days, and glucocorticoid therapy.
  • Effective identification and antibiotic treatment of H.Pylori infections is also crutial in preventing complications including upper GI bleeding.
  • In regards to the prevention of NSAID-related peptic ulcer disease and complicating upper GI bleed: patients are at the highest risk for NSAID-induced GI toxicity when they have any of these risk factors:
  1. A history of an ulcer or GI hemorrhage
  2. Age >60
  3. High dosage of a NSAID
  4. Concurrent use of glucocorticoids
  5. Concurrent use of anticoagulants

In these patients, the use of COX-2 selective inhibitor or a nonselective NSAID in combination with a PPI or misoprostol is indicated. In addition, patients with a history of uncomplicated or complicated peptic ulcers should be tested for H. pylori prior to beginning a NSAID or low dose aspirin. If present, H. pylori should be treated with appropriate therapy, even if it is believed that the prior ulcer was due to NSAIDs.

Related Chapters

External links

ar:قيء دموي de:Hämatemesis


Template:WikiDoc Sources